Ferrando L, Vingiani A, Garuti A, Vernieri C, et al. ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC). PLoS Genet 2023;19:e1010563.
PMID: 36595552